Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Back to Journals Drug, Healthcare and Patient Safety Volume 18 Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method Authors Gu S Received 29 July 2025 Accepted for publication 3 January 2026 Published 8 January 2026 Volume 2026:18 556918 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Professor Siew Siang Chua Saisai Gu Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Peoples Republic of China Correspondence: Saisai Gu, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Peoples Republic of China, Email [email protected] Purpose: Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals
Focusing on a customer-centric approach, NEXLIFE BIOSCIENCE PRIVATE LIMITED has a pan-India presence and caters to a huge consumer base throughout the country
Lastly, while some side effects are possible, GLP-1 agonists have been shown to be safe and well-tolerated in clinical studies
It also incorporates B vitamins to support your metabolism and reduce fatigue, as well as choline to target fat breakdown
2017;27(21):R114751
US$ 22.78
US$ 29.53
US$ 27.80
US$ 20.28
